Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Kodiak Completes Business Combination with Ares Acquisition Corporation II to Accelerate Journey as a Leading AI-Powered Autonomous Vehicle Technology Company
-
ZOOZ Shareholders Approve Previously Announced $180 Million Private Placement and Bitcoin Treasury Reserve Strategy, Along with All Related Proposals
-
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
-
Apnimed to Participate in Upcoming September Investor Conferences
-
Chardan Capital Markets Starts Ocular Therapeutix (OCUL) at Buy
-
WestPark Capital Announces the Hiring of Priyanka Mahajan as Managing Director of Investment Banking
-
Chardan Capital Markets Downgrades Tourmaline Bio (TRML) to Neutral
-
AlphaTON Capital raises $100 million to build TON digital asset treasury
-
AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem
-
AlphaTON Capital raises $73M to build TON token treasury
-
AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem
-
BT Brands to merge with drone services company Aero Velocity
-
BT Brands and Aero Velocity Announce Execution of Definitive Merger Agreement
-
US FDA declines to approve Outlook Therapeutics' eye disease drug, shares plummet
-
Krystal Biotech (KRYS) PT Lowered to $216 at Chardan Capital Markets
-
Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell
-
Prime Medicine (PRME) PT Lowered to $10 at Chardan Capital Markets, 'Cash Runway Breathing Room'
-
SAB Biotherapeutics (SABS) PT Lowered to $12 at Chardan Capital Markets
-
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
-
Senti Bio reports Q2 2025 results, confirms AML data expected Q4
-
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025
-
Sensorion Announces Its Participation In Upcoming Investor Conferences
-
Form D Chardan Holdings LP
-
ZOOZ Announces Private Placement of $180 Million to Launch a Bitcoin Treasury Reserve Strategy
-
SAB BIO Announces Oversubscribed $175 Million Private Placement
-
Smith Micro Announces Closing of Follow-On Offering
-
Chardan Capital Markets Downgrades Clearside Biomedical (CLSD) to Neutral
-
Smith Micro raises $1.5 million through stock offering and warrants
-
Bit Origin raises $500 million to build dogecoin treasury strategy
-
Smith Micro Announces Follow-On Offering
-
Bit Origin Secures $500 Million Equity and Debt Facilities to Launch Dogecoin Treasury
-
Sonnet BioTherapeutics agrees to $888 million crypto treasury deal
-
Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy
-
Chardan Capital Markets Starts Urgent.ly (ULY) at Buy
-
Chardan: 'We think CRSP's emergence as a credible player in the space could thus drive further valuation upside'
-
Chardan Comments on iBio, Inc. (IBIO)
-
Forte Biosciences Announces Pricing of $75 Million Public Offering
-
Forte Biosciences (FBRX) Announces Proposed Share Offering
-
Forte Biosciences Announces Proposed Public Offering
-
Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program
-
Carisma Therapeutics (CARM) to Merge with Ocugen's (OCGN) OrthoCellix
-
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
-
Chardan Capital Markets Starts Monopar Therapeutics (MNPR) at Buy, PT $60
-
Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings
-
Lion Group Holding (LGHL) Secures $600M Facility to Launch Hyperliquid (HYPE) Treasury
-
LGHL Secures $600 Million Facility to Launch Hyperliquid (HYPE) Treasury
-
Wedbush Securities Expands Trading Leadership with the Hiring of Michael Bower and George Nikitiadis as Managing Directors
-
Eyenovia (EYEN) Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy
-
Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy
-
Chardan Capital Markets Reiterates Buy Rating on Dyne Therapeutics (DYN) Following FDA Update

